US EditionPublished • loading... • Updated
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
Summary by diagnosticimaging.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Telix Highlights ProstACT Global, CUPID and STARLITE Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2025
Melbourne (Australia) and Indianapolis, IN (U.S.) | 30 May 2025 Telix today announces four accepted abstracts (three presentations) featuring the Company’s investigational therapeutic radiopharmaceutical programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from today, May 30, through June 3, 2025. Scott Tagawa MD, Professor of Medicine & Urology Weill Cornell Medicine (NY) will presen…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
